| Revenue growth | H1 total income +221% YoY; Q2 +536% vs comparator |
|---|---|
| Margins | Q2 EBITDA margin 12.47%; H1 16.27% vs 8.83% prior |
| Demand visibility | Blending demand 1,200 crore litres; supply broadly matches |
| Management confidence | Cautious; cites volatility and cyclical feedstock constraints |
Growth
Q2 total income ₹823.74 Cr (+536% vs ₹129.56 Cr comparator). H1 total income ₹1,465.14 Cr (+221% YoY). Ethanol H1 PAT ₹89.32 Cr (+307%).
Outlook
CBG Mudhol commissioning Nov 2026; Kedarnath and Badami Dec 2026. Ethanol units Q3/Q4 FY27. SAF 100 MLPA project awaits blending roadmap.
Risks
Maize ₹18 to ₹25/kg squeezed margins. CBG profit fell as MDA subsidy ended after 31 Aug 2026. Thin ethanol supply cushion of 4 crore litres.
Last quarter's promises, checked
Delivered
- Guided 'fairly good growth' in Q2 → Q2 total income ₹823.74 Cr, +536% YoY (= BEAT)
Partly delivered
- Guided CBG ~₹10–12 Cr/qtr run-rate → CBG -3%, ₹ level not disclosed (= PARTIAL)
- Guided 3 Sumitomo CBG plants live by Q3 FY27 → Mudhol Nov, Kedarnath/Badami Dec 2026 (= PARTIAL)
Missed
- Guided 'decent' Q2 margins off Q1 23.5% EBITDA → Q2 EBITDA 12.47% (= MISS)
- Guided CBG PAT 40–50%, no margin change → CBG profit fell on MDA end (= MISS)
- Guided SAF capex start in 2–3 months → still awaiting blending roadmap (= MISS)
Investor Presentation filed with BSE, NSE: TRUALT. Summary written with AI assistance from the document.
TruAlt Bioenergy Ltd: key numbers
- Share price
- ₹377.00
- Market cap
- ₹3,233 Cr
- Revenue (annual)
- ₹1,728 Cr
- Net profit (annual)
- ₹95.95 Cr
- P/E (TTM)
- 14.6×Sector 26.8×
- Promoter holding
- 71.38%+0.83% QoQ
- FII holding
- 0.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from TruAlt Bioenergy Ltd
All →TruAlt Bioenergy Earnings Call Transcript: Key Takeaways
TruAlt reported massive 606% YoY revenue growth, turning profitable despite raw material price surges. Management is pivoting from ethanol to high-margin CBG to insulate from feedstock volatility.
TruAlt Bioenergy Results Update
TruAlt Bioenergy reported H1 FY27 revenue of ₹1,437.98 crore, EBITDA of ₹233.92 crore and PAT of ₹94.27 crore via press release. Results reverse last year's H1 loss.
TruAlt Bioenergy Q2 FY27 Results: Turns Profitable, Net Profit ₹35 Cr
TruAlt Bioenergy Ltd reported revenue from operations of ₹811.1 Cr (+605.9% YoY) and net profit of ₹35 Cr for Q2 FY27.
- Key figure
- Net profit ₹35 Cr
TruAlt Bioenergy Management Change
Mr. Monu Kumar resigned as Company Secretary and Compliance Officer of TruAlt Bioenergy Limited, effective October 16, 2026, due to personal reasons.
TruAlt Bioenergy Other Announcement
The company submitted its quarterly shareholding pattern for the period ended September 30, 2026, as required by regulatory compliance.
TruAlt Bioenergy Board Meeting Date
TruAlt Bioenergy announced a board meeting on October 23, 2026, to consider and approve unaudited financial results for the quarter and half-year ended September 30, 2026.